Articles By Jack Cush, MD
NIH Discovers Otulipenia - New Infantile Autoinflammatory Disorder
Researchers at the National Institutes of Health, led by Dr. Dan Kastner, have led the way in the discovery and understanding of numerous autoinflammatory diseases.
Read Article
Another Biosimilar Approval - Etanercep-szzs by Novartis
Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.
Read Article
HMGB1 as a Biomarker for Polymyositis and Dermatomyositis
High mobility group box chromosomal protein 1 (HMGB1) is a DNA-binding protein that functions as a structural co-factor. HMGB1 is actively secreted by macrophage/monocytes via inflammatory stimuli and is elaborated during apoptosis.
Read Article
FDA Approves Updated Denosumab Warnings
In 2015, the Food and Drug Administration (FDA) updated the warnings of all marked bisphosphonates to include the risk of osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).
Read Article
Zurampic Helps Allopurinol Non-Responders
Lesinurad (Zurampic) was approved earlier this year as adjunctive therapy to other urate-lowering therapies. It is a selective uric acid reabsorption inhibitor (URAT-1 inhibitor) designed to treat gout, and be used in combination with other xanthine oxidase inhibitors.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab
Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.
Read Article
Adalimumab Controls Non-Infectious Uveitis in VISUAL II Study
It has long been observed that patients receiving monoclonal antibody based anti-TNF (TNFi) therapies for spondylitis or psoriatic disease have less inflammatory eye complications, such as uveitis. These agents have become common interventions based on these observational results.
Read Article
Go Ahead, Jump!
You write the prescription, hand it to the patient and explain why it’s needed, how to take it and what the most common or most dangerous side effects might be. Comprehensive, reasonable, and professional. Certainly the patient should fill the prescription and start the drug.
Read Article
Drug Use Compounds Risk - Before and After Fragility Fractures
Is the occurrence of a fragility fracture a missed opportunity to reduce exposure to prescription drugs associated with fracture risk?
Read Article
